Previous Close | 6.85 |
Open | 6.86 |
Bid | 6.72 x 200 |
Ask | 6.81 x 200 |
Day's Range | 6.76 - 7.17 |
52 Week Range | 0.76 - 9.39 |
Volume | |
Avg. Volume | 2,222,898 |
Market Cap | 720.032M |
Beta (5Y Monthly) | 1.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.42 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for APLT
The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday. There are currently no approved treatments for the disease in the United States, which has about 3,000 Galactosemia patients. The FDA delayed its decision on the drug, govorestat, saying it requires additional time to review supplemental analyses submitted by the company.
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months. The FDA has set a new Prescri
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.